Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

NCT00371553 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

British Columbia Cancer Agency

Collaborators